Home >> Pharmaceuticals >> Food & Beverage >>

Treatment Resistant Depression - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 61 | Code: MRS - 18257

Treatment Resistant Depression - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Treatment Resistant Depression - Pipeline Review, H1 2015’, provides an overview of the Treatment Resistant Depression’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Treatment Resistant Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Treatment Resistant Depression and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Treatment Resistant Depression and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Treatment Resistant Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Treatment Resistant Depression pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Treatment Resistant Depression
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Treatment Resistant Depression pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Treatment Resistant Depression Overview 7
Therapeutics Development 8
Pipeline Products for Treatment Resistant Depression - Overview 8
Pipeline Products for Treatment Resistant Depression - Comparative Analysis 9
Treatment Resistant Depression - Therapeutics under Development by Companies 10
Treatment Resistant Depression - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Treatment Resistant Depression - Products under Development by Companies 15
Treatment Resistant Depression - Companies Involved in Therapeutics Development 16
Addex Therapeutics Ltd 16
Amorsa Therapeutics Inc. 17
Edgemont Pharmaceuticals, LLC 18
F. Hoffmann-La Roche Ltd. 19
Johnson & Johnson 20
MarcoPolo Pharmaceuticals SA 21
Otsuka Holdings Co., Ltd. 22
Treatment Resistant Depression - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 32
(dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AVP-786 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
basimglurant - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
BC-19 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
EDG-006 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
esketamine hydrochloride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
EVT-100 Series - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
EVT-103 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
KA-ER12 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
KA-FA - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecule to Modulate Glutamate Receptor for Anxiety Disorders - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules to Inhibit mGluR2 for Central Nervous System Disorders - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Treatment Resistant Depression - Recent Pipeline Updates 50
Treatment Resistant Depression - Dormant Projects 57
Treatment Resistant Depression - Discontinued Products 58
Treatment Resistant Depression - Product Development Milestones 59
Featured News & Press Releases 59
Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis 59
Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

List of Tables
Number of Products under Development for Treatment Resistant Depression, H1 2015 8
Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Comparative Analysis by Unknown Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Treatment Resistant Depression - Pipeline by Addex Therapeutics Ltd, H1 2015 16
Treatment Resistant Depression - Pipeline by Amorsa Therapeutics Inc., H1 2015 17
Treatment Resistant Depression - Pipeline by Edgemont Pharmaceuticals, LLC, H1 2015 18
Treatment Resistant Depression - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 19
Treatment Resistant Depression - Pipeline by Johnson & Johnson, H1 2015 20
Treatment Resistant Depression - Pipeline by MarcoPolo Pharmaceuticals SA, H1 2015 21
Treatment Resistant Depression - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Assessment by Combination Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 31
Treatment Resistant Depression Therapeutics - Recent Pipeline Updates, H1 2015 50
Treatment Resistant Depression - Dormant Projects, H1 2015 57
Treatment Resistant Depression - Discontinued Products, H1 2015 58

List of Figures
Number of Products under Development for Treatment Resistant Depression, H1 2015 8
Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 12
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Top 10 Targets, H1 2015 25
Number of Products by Stage and Top 10 Targets, H1 2015 26
Number of Products by Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Top 10 Routes of Administration, H1 2015 29
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30
Number of Products by Stage and Top 10 Molecule Types, H1 2015 31

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing